1. Technological Advancements in Monoclonal Antibodies
   José F. Santos-Neto et al, 2021, The Scientific World Journal CrossRef
2. Antibody drug conjugates: hitting the mark in pancreatic cancer?
   Nicole L. Wittwer et al, 2023, Journal of Experimental & Clinical Cancer Research CrossRef
3. Antibody-drug conjugates: beyond current approvals and potential future strategies
   Siddharth Menon et al, 2022, Exploration of Targeted Anti-tumor Therapy CrossRef
4. Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
   Weiliang Zhuang et al, 2023, International Journal of Molecular Sciences CrossRef
5. Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
   Ryo Tsumura et al, 2024, Cancer Science CrossRef
6. Delivery strategies of immunotherapies in the treatment of pancreatic cancer
   Manoj Kumar Gupta et al, 2024, Immune Landscape of Pancreatic Cancer Development and Drug Resistance CrossRef
7. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
   Gustavo A. Arias-Pinilla et al, 2021, Cancers CrossRef
8. Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis
   Makoto Miyazaki et al, 2023, Cancer Letters CrossRef
9. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
   Charalampos Theocharopoulos et al, 2024, Cancer Treatment Reviews CrossRef
10. Radioimmunotherapy with an 211At‐labeled anti–tissue factor antibody protected by sodium ascorbate
    Hiroki Takashima et al, 2021, Cancer Science CrossRef
11. Advancing Tissue Factor-targeted Therapy for Osteosarcoma via Understanding its Role in the Tumor Microenvironment
    Jiro Ichikawa et al, 2023, Current Pharmaceutical Design CrossRef